A. Lardy-Cleaud

NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.

C. Borel, V. Costes, D. Cupissol, 2019, Journal of Clinical Oncology.